MAEDA S, MATSOUKA M, KAI M, NAKATA N, MAEDA Y, KASHIWABARA Y; Interscience Conference on Antimicrobial Agents and Chemotherapy.
Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. 1999 Sep 26-29; 39: 107 (abstract no. 816).
Leprosy Res. Ctr., Natl. Inst. of Infectious Diseases, Tokyo, JAPAN.
Fluoroquinolones, which are potent, broad-spectrum antimicrobial agents, are increasingly used in the treatment of infectious diseases. Ofloxacin, one of fluoroquinolones, has been introduced to the regimens of multidrug therapy (MDT) of WHO for leprosy. Although acquired resistance to fluoroquinolones has commonly been observed for many bacterial species, it has not been reported in Mycobacterium leprae except a lepromatous leprosy patient in Mali. The sequences of quinolone resistance determining region (QRDR) of the gyrA gene, the mutational alteration of which has been reported to lead the resistance to quinolones, were analyzed for 13 clinical isolates of M. leprae. 8 of 13 showed the mutations in this region, suggesting the development of fluoroquinolone-resistance. Moreover, 5 of the 8 strains showed mutations in the rpoB gene, suggesting that these strains have acquired resistance to both rifampicin and quinolones. Our results suggest that the survey and the new regimens for drug resistant strains are required for both therapy and prevention of multidrug resistance.
Publication Types:
Keywords:
- Anti-Infective Agents
- Base Sequence
- Drug Resistance, Multiple
- Fluoroquinolones
- Humans
- Leprosy
- Leprosy, Lepromatous
- Mali
- Mutation
- Mycobacterium leprae
- Ofloxacin
- Quinolones
- Rifampin
- genetics
Other ID:
UI: 102244939
From Meeting Abstracts